Cargando…

Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect

We investigated a polyethylene glycol non-precipitable low-density lipoprotein (LDL) subfraction targeted by IgG and the influence of statin therapy on plasma levels of these small LDL-IgG-immune complexes (LDL-IgG-IC). LDL-subfractions were isolated from 6 atherosclerotic subjects and 3 healthy ind...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hörl, Gerd, Froehlich, Harald, Ferstl, Ulrika, Ledinski, Gerhard, Binder, Josepha, Cvirn, Gerhard, Stojakovic, Tatjana, Trauner, Michael, Koidl, Christoph, Tafeit, Erwin, Amrein, Karin, Scharnagl, Hubert, Jürgens, Günther, Hallström, Seth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739583/ https://www.ncbi.nlm.nih.gov/pubmed/26840480 http://dx.doi.org/10.1371/journal.pone.0148210

Ejemplares similares

Ethyl pyruvate inhibits oxidation of LDL in vitro and attenuates oxLDL toxicity in EA.hy926 cells
por: Rossmann, Christine, et al.
Publicado: (2018)

The anticoagulant effects of ethyl pyruvate in whole blood samples
por: Haidl, Harald, et al.
Publicado: (2020)

Metformin Impedes Oxidation of LDL In Vitro
por: Rossmann, Christine, et al.
Publicado: (2023)

A low-fat spread with added plant sterols and fish omega-3 fatty acids lowers serum triglyceride and LDL-cholesterol concentrations in individuals with modest hypercholesterolaemia and hypertriglyceridaemia
por: Blom, Wendy A. M., et al.
Publicado: (2018)

Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE(−/−) Mice
por: Gu, Lili, et al.
Publicado: (2019)

LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor™) in Thai hypercholesterolemic subjects – a randomized crossover study, the first report from Thailand
por: Wiwanitkit, Viroj, et al.
Publicado: (2002)

Supplementation with a juice powder concentrate and exercise decrease oxidation and inflammation, and improve the microcirculation in obese women: randomised controlled trial data
por: Lamprecht, Manfred, et al.
Publicado: (2013)

Endothelial lipase increases antioxidative capacity of high-density lipoprotein
por: Schilcher, Irene, et al.
Publicado: (2019)

Cardiac involvement in a cross‐sectional cohort of myotonic dystrophies and other skeletal myopathies
por: Schmid, Johannes, et al.
Publicado: (2020)

Cultivation and Immortalization of Human B-Cells Producing a Human Monoclonal IgM Antibody Binding to MDA-LDL: Further Evidence for Formation of Atherogenic MDA-LDL Adducts in Humans In Vivo
por: Tatzber, Franz, et al.
Publicado: (2017)

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
por: Konrad, Robert J, et al.
Publicado: (2011)

FXR controls CHOP expression in steatohepatitis
por: Fuchs, Claudia D., et al.
Publicado: (2017)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
por: Baigent, Colin, et al.
Publicado: (2011)

Lipid-lowering therapies and achievement of LDL-cholesterol targets
por: Rizzo, Manfredi, et al.
Publicado: (2012)

Bioactivity of Dietary Polyphenols: The Role in LDL-C Lowering
por: Sun, Peng, et al.
Publicado: (2021)

oxLDL and eLDL Induced Membrane Microdomains in Human Macrophages
por: Wallner, Stefan, et al.
Publicado: (2016)

Complementary Therapy to Target LDL Cholesterol: The Role of the Ezetimibe/Simvastatin Combination
por: Neal, Ryan C, et al.
Publicado: (2006)

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial
por: Heart Protection Study Collaborative Group
Publicado: (2011)

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
por: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group
Publicado: (2010)

LDL-C: lower is better for longer—even at low risk
por: Penson, Peter E., et al.
Publicado: (2020)

New and emerging lipid-modifying drugs to lower LDL cholesterol
por: Kosmas, Constantine E, et al.
Publicado: (2021)

LDL lowering effect of PCSK9 inhibition is reduced in women
por: Myasoedova, Veronika A, et al.
Publicado: (2023)

Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?
por: Khan, Safi U., et al.
Publicado: (2020)

Orthostatic Challenge Shifts the Hemostatic System of Patients Recovered from Stroke toward Hypercoagulability
por: Cvirn, Gerhard, et al.
Publicado: (2017)

ZNF542P is a pseudogene associated with LDL response to simvastatin treatment
por: Kim, Kyungpil, et al.
Publicado: (2018)

Superparamagnetic iron oxide nanoparticles for their application in the human body: Influence of the surface
por: Turrina, Chiara, et al.
Publicado: (2023)

Short-term LDL cholesterol-lowering efficacy of plant stanol esters
por: Hallikainen, Maarit, et al.
Publicado: (2002)

Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
por: Krähenbühl, Stephan, et al.
Publicado: (2016)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
por: Storey, Benjamin C., et al.
Publicado: (2018)

Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency
por: Tarasov, Kirill, et al.
Publicado: (2014)

Orthostatic Challenge-Induced Coagulation Activation in Young and Older Persons
por: Schlagenhauf, Axel, et al.
Publicado: (2022)

LDL-Cholesterol Lowering of Plant Sterols and Stanols—Which Factors Influence Their Efficacy?
por: Trautwein, Elke A., et al.
Publicado: (2018)

Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk
por: Rikhi, Rishi, et al.
Publicado: (2022)

Oxidized LDL Is Strictly Limited to Hyperthyroidism Irrespective of Fat Feeding in Female Sprague Dawley Rats
por: Zelzer, Sieglinde, et al.
Publicado: (2015)

Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2(−/−) mouse model of sclerosing cholangitis via immunomodulatory effects
por: Fuchs, Claudia D., et al.
Publicado: (2022)

Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting
por: Dent, Ricardo, et al.
Publicado: (2016)

Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia
por: Kastelein, John J.P., et al.
Publicado: (2017)

Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes
por: Arnold, Suzanne V., et al.
Publicado: (2020)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019)

Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
por: Albosta, Michael S, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kepgj7b7vtuedfigaedtje7gd6